Citius Oncology (CTOR): תחזית צמיחת רווחים לשנה הבאה

Citius Oncology, Inc. (CTOR) minimizes regulatory risks by developing a diverse range of therapies for solid and hematological tumors. This 12-month EPS growth chart reflects analyst forecast trends, with the current level sitting around 58.40. Following its IPO, Citius Oncology, Inc. (CTOR) is scaling sales of its T-cell lymphoma drug in the US, although the lack of commercial products renders cash flows unstable.

This indicator reflects the analysts' consensus estimate for earnings per share growth rates, determining the asset's future value. The trend of this metric allows investors to filter out market noise and assess the real potential for profit growth. The current annual EPS growth forecast for the company is fixed at 58.40. For Citius Oncology, Inc. (CTOR), this metric is critical, as the lack of sales and the costs associated with therapy approval create high business survival risks.